Head to Head Comparison: Daré Bioscience (NASDAQ:DARE) vs. Insmed (NASDAQ:INSM)

Insmed (NASDAQ:INSM) and Daré Bioscience (NASDAQ:DARE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, risk, earnings, valuation, institutional ownership and dividends.

Risk & Volatility

Insmed has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Daré Bioscience has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500.

Profitability

This table compares Insmed and Daré Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Insmed	-245.59%	N/A	-53.34%
Daré Bioscience	N/A	-1,482.38%	-120.75%

Insider and Institutional Ownership

6.7% of Daré Bioscience shares are owned by institutional investors. 4.6% of Insmed shares are owned by insiders. Comparatively, 5.3% of Daré Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Insmed and Daré Bioscience’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$305.21 million	13.05	-$749.57 million	($5.34)	-5.02
Daré Bioscience	$2.81 million	17.18	-$30.16 million	($0.34)	-1.41

Daré Bioscience has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Daré Bioscience, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Insmed and Daré Bioscience, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	0	0	11	0	3.00
Daré Bioscience	0	1	1	0	2.50

Insmed currently has a consensus price target of $44.64, indicating a potential upside of 66.43%. Daré Bioscience has a consensus price target of $6.00, indicating a potential upside of 1,149.74%. Given Daré Bioscience’s higher possible upside, analysts clearly believe Daré Bioscience is more favorable than Insmed.

Summary

Daré Bioscience beats Insmed on 9 of the 14 factors compared between the two stocks.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

About Daré Bioscience

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy. The company's Phase I-ready products are DARE-VVA1, a proprietary formulation of tamoxifen for intravaginal to treat vulvar vaginal atrophy in women with hormone-receptor positive breast cancer; DARE-PDM1, a proprietary hydrogel formulation of diclofenac, a nonsteroidal anti-inflammatory drug, for vaginal administration as a treatment for dysmenorrhea; DARE-204 and DARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-GML, an intravaginally-delivered potential multi-target antimicrobial agent formulated with glycerol monolaurate; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. was incorporated in 2005 and is headquartered in San Diego, California.